A federal court today denied the Department of Health and Human Services’ motion for a stay in a lawsuit brought by the AHA, Association of American Medical Colleges, America’s Essential Hospitals, 340B Health and three hospital systems challenging the excessive delay in the effective date for the 340B price transparency rule. The judge ordered HHS to file by Nov. 13 its opposition to the plaintiffs’ motion for summary judgment and any cross motion and motion to dismiss. AHA and the other plaintiffs last month urged the court to reject HHS’s motion for a stay in the case.
 
The AHA and other groups in September asked a federal court to order HHS to make effective within 30 days a final rule requiring drug companies to disclose the ceiling price for 340B outpatient drugs. To ensure accuracy and compliance with the 340B drug savings program, the rule also describes how ceiling prices must be calculated and would allow the federal government to levy civil monetary penalties against drug companies that intentionally overcharge 340B providers.
 
Facing deadlines for responding to the lawsuit, HHS this week published a proposed rule to move up to Jan. 1 the effective date of the final rule. HHS will accept comments through Nov. 21 on its proposal. Today’s decision puts more pressure on HHS to stick to the Jan. 1 deadline for making the final rule effective.

Headline
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…
Headline
The Washington Post yesterday published a letter to the editor from AHA President and CEO Rick Pollack responding to an April 18 editorial criticizing the 340B…
Headline
The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program because “a rebate mechanism of any kind…
Headline
The AHA and others April 17 filed an amicus brief requesting the U.S. Court of Appeals for the 4th Circuit grant en banc review of a panel decision that…
Headline
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…
Headline
The U.S. District Court for the District of Columbia March 31 vacated a Health Resources and Services Administration policy instituted in 2013 that restricted…